These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8953104

  • 1. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
    Kato N, Kato H, Tanaka-Bando K, Watanabe K, Ueno K.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM, Molitoris E, Reeves D, Finegold SM.
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA, Jones RN.
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [Abstract] [Full Text] [Related]

  • 5. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
    Nakane T, Iyobe S, Sato K, Mitsuhashi S.
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2822-6. PubMed ID: 8593031
    [Abstract] [Full Text] [Related]

  • 6. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
    Goldstein EJ.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
    [Abstract] [Full Text] [Related]

  • 7. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW, Wexler HM.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients.
    Mikamo H, Sato Y, Hayasaki Y, Kawazoe K, Tamaya T.
    Chemotherapy; 1999 Dec; 45(3):154-7. PubMed ID: 10224336
    [Abstract] [Full Text] [Related]

  • 9. DU-6859a, a new fluoroquinolone agent. Comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli.
    Tomayko JF, Korten V, Murray BE.
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):45-7. PubMed ID: 7867298
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
    Saito H, Tomioka H, Sato K, Dekio S.
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ, Citron DM, Warren Y, Tyrrell K, Merriam CV.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.
    Spangler SK, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1997 Apr; 41(4):847-9. PubMed ID: 9087503
    [Abstract] [Full Text] [Related]

  • 17. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
    Morrissey I, Smith JT.
    J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954
    [Abstract] [Full Text] [Related]

  • 18. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS, Sanders CC.
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [Abstract] [Full Text] [Related]

  • 19. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA, Jones RN, Murray PR, Washington JA, Allen SD, Gerlach EH, Erwin ME.
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract] [Full Text] [Related]

  • 20. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.